Scilex Holding Co
NASDAQ:SCLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Scilex Holding Co
Other Non-Cash Items
Scilex Holding Co
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
Other Non-Cash Items
$23.7m
|
CAGR 3-Years
1 579%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Non-Cash Items
$1.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Non-Cash Items
$4.5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
14%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Non-Cash Items
$4.8B
|
CAGR 3-Years
68%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Non-Cash Items
$1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Non-Cash Items
$4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Scilex Holding Co
Glance View
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
See Also
What is Scilex Holding Co's Other Non-Cash Items?
Other Non-Cash Items
23.7m
USD
Based on the financial report for Dec 31, 2023, Scilex Holding Co's Other Non-Cash Items amounts to 23.7m USD.
What is Scilex Holding Co's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
1 579%
The average annual Other Non-Cash Items growth rates for Scilex Holding Co have been 1 579% over the past three years .
